ATE489967T1 - Hcv-vakzin - Google Patents

Hcv-vakzin

Info

Publication number
ATE489967T1
ATE489967T1 AT04763141T AT04763141T ATE489967T1 AT E489967 T1 ATE489967 T1 AT E489967T1 AT 04763141 T AT04763141 T AT 04763141T AT 04763141 T AT04763141 T AT 04763141T AT E489967 T1 ATE489967 T1 AT E489967T1
Authority
AT
Austria
Prior art keywords
epitope
hcv
vaccine
hcv vaccine
hotspot
Prior art date
Application number
AT04763141T
Other languages
English (en)
Inventor
Michael Buschle
Juergen Frisch
Christoph Klade
Karen Lingnau
Wolfgang Zauner
Gerd Zettlmeissl
Original Assignee
Intercell Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Ag filed Critical Intercell Ag
Application granted granted Critical
Publication of ATE489967T1 publication Critical patent/ATE489967T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT04763141T 2003-07-11 2004-07-09 Hcv-vakzin ATE489967T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03450171 2003-07-11
EP04450062 2004-03-12
PCT/EP2004/007540 WO2005004910A2 (en) 2003-07-11 2004-07-09 Hcv vaccines

Publications (1)

Publication Number Publication Date
ATE489967T1 true ATE489967T1 (de) 2010-12-15

Family

ID=34066530

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04763141T ATE489967T1 (de) 2003-07-11 2004-07-09 Hcv-vakzin

Country Status (11)

Country Link
US (3) US20070031446A1 (de)
EP (2) EP2275131A3 (de)
JP (2) JP4734241B2 (de)
CN (1) CN1822856B (de)
AT (1) ATE489967T1 (de)
AU (1) AU2004255456B2 (de)
CA (1) CA2530062A1 (de)
DE (1) DE602004030343D1 (de)
PL (1) PL1648502T3 (de)
TW (1) TWI358301B (de)
WO (1) WO2005004910A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE464907T1 (de) 1999-02-17 2010-05-15 Csl Ltd Immunogene komplexe und methoden in bezug auf diese
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT410635B (de) * 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
CN1753687A (zh) 2002-10-29 2006-03-29 科勒制药集团股份有限公司 Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
ATE489967T1 (de) * 2003-07-11 2010-12-15 Intercell Ag Hcv-vakzin
ATE381945T1 (de) * 2004-03-12 2008-01-15 Intercell Ag Verfahren zur solubilisierung von peptid- mischungen
US20090060875A1 (en) * 2004-10-29 2009-03-05 Intercell Ag HCV Vaccines for Chronic HCV Patients
JP2008532559A (ja) * 2005-03-19 2008-08-21 メディカル リサーチ カウンシル ウイルス感染の治療及び予防又は治療及び予防の改善
CN101426514A (zh) * 2006-04-25 2009-05-06 英特塞尔股份公司 Hcv疫苗
KR101251707B1 (ko) 2006-09-27 2013-04-11 콜리 파마슈티칼 게엠베하 면역 자극 활성이 증강된 소수성 Ｔ 유사체를 함유하는 ＣｐＧ 올리고뉴클레오티드 유사체
US20110217265A1 (en) * 2008-09-23 2011-09-08 Glenn Jeffrey S Screening for Inhibitors of HCV Amphipathic Helix (AH) Function
WO2010054446A1 (en) * 2008-11-11 2010-05-20 Ademovic Zlatko Combination of two or more peptides in a single stable lyophilized pharmaceutical compound
CN102378914B (zh) * 2009-03-30 2014-12-10 生物梅里埃公司 用于hcv检测的固体支持物
WO2010148117A1 (en) 2009-06-17 2010-12-23 Scantibodies Laboratory, Inc. Therapeutic and diagnostic affinity purified specific polyclonal antibodies
EP2484378A4 (de) 2009-09-30 2013-05-22 Toray Industries Hepatitis-c-virus-impfstoffzusammensetzung
US8765148B2 (en) 2010-02-19 2014-07-01 Valneva Austria Gmbh 1C31 nanoparticles
US9752494B2 (en) 2013-03-15 2017-09-05 Kohler Co. Noise suppression systems
EP3289083A4 (de) 2015-04-27 2018-12-19 The Trustees Of The University Of Pennsylvania Nukleosidmodifizierte rna zur induktion einer adaptiven immunantwort
EP3618859A4 (de) * 2017-04-27 2021-05-05 Vanderbilt University Hepatitis-c-virusgensequenzen und verwendungsverfahren dafür
CN109212220B (zh) * 2018-09-21 2021-06-29 北京凯因科技股份有限公司 丙型肝炎病毒抗体快速检测试纸条

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683864A (en) * 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
DE3834729A1 (de) * 1988-10-12 1990-04-19 Behringwerke Ag Verwendung von zink-oder eisenhydroxid zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen
US5562910A (en) * 1989-09-25 1996-10-08 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
CA2090335A1 (en) 1990-08-25 1992-02-26 Suzanne Zebedee Non-a, non-b hepatitis virus antigen, diagnostic methods and vaccines
HU227547B1 (en) 1991-06-24 2011-08-29 Novartis Vaccines & Diagnostic Hepatitis c virus (hcv) polypeptides
US6419931B1 (en) 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US20030152580A1 (en) * 1994-07-21 2003-08-14 Alessandro Sette Hla binding peptides and their uses
US5333965A (en) 1992-01-31 1994-08-02 Mailey John W In situ modular fastening system
JP3908271B2 (ja) 1993-03-05 2007-04-25 エピミューン，インコーポレイティド Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用
CA2139100C (en) 1993-04-27 2009-06-23 Geert Maertens New sequences of hepatitis c virus genotypes and their use as therapeutic and diagnostic agents
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
EP0754193B1 (de) 1994-04-08 2000-06-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES Peptid aus dem inneren des hepatitis-c-virus brauchbar für die stimulation cytotoxischer t-lymphocyten und die diagnose des hcv-kontaktes
AUPM543894A0 (en) * 1994-05-04 1994-05-26 Commonwealth Scientific And Industrial Research Organisation An adjuvant
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
US6231859B1 (en) * 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
EP0855184A1 (de) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
ES2278411T3 (es) * 1997-05-01 2007-08-01 Protechtion Unlimited, Inc. Factor de crecimiento nervioso como adyuvante de vacuna.
DE19803453A1 (de) 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
US6685944B1 (en) 1998-08-21 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Modified HCV peptide vaccines
CA2377525A1 (en) * 1999-07-19 2001-03-29 Epimmune Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
AT408721B (de) * 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
US20090130135A1 (en) * 1999-10-01 2009-05-21 Michael Buschle Hcv vaccines
AT409085B (de) * 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
EP1272215B1 (de) 2000-04-14 2007-10-10 Intercell AG Modifizierte peptide enthaltende pharmazeutische präparationen
DE60100814T2 (de) * 2000-06-08 2004-07-01 Intercell Biomedizinische Forschungs- Und Entwicklungs Gmbh Immunstimulierende oligodeoxynukleotide
WO2002013857A2 (en) 2000-08-17 2002-02-21 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
AT410635B (de) * 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US6588670B2 (en) * 2001-10-30 2003-07-08 Symbol Technologies, Inc. Medical diagnostic monitoring
WO2003047602A1 (en) * 2001-12-07 2003-06-12 Intercell Ag Immunostimulatory oligodeoxynucleotides
FR2843115B1 (fr) * 2002-08-02 2007-11-09 Commissariat Energie Atomique Melange de peptides issus des proteines c et ns3 du virus de l'hepatite c et leurs applications
WO2004024182A2 (en) 2002-09-13 2004-03-25 Intercell Ag Method for isolating hepatitis c virus peptides
US7704514B2 (en) * 2003-03-24 2010-04-27 Intercell Ag Vaccines
ATE489967T1 (de) * 2003-07-11 2010-12-15 Intercell Ag Hcv-vakzin
US20090060875A1 (en) * 2004-10-29 2009-03-05 Intercell Ag HCV Vaccines for Chronic HCV Patients

Also Published As

Publication number Publication date
WO2005004910A2 (en) 2005-01-20
EP2275131A3 (de) 2012-01-25
US20070031446A1 (en) 2007-02-08
US20090155294A1 (en) 2009-06-18
WO2005004910A3 (en) 2005-04-21
US20110300170A1 (en) 2011-12-08
CA2530062A1 (en) 2005-01-20
EP2275131A2 (de) 2011-01-19
JP4734241B2 (ja) 2011-07-27
TWI358301B (en) 2012-02-21
EP1648502A2 (de) 2006-04-26
PL1648502T3 (pl) 2011-05-31
CN1822856A (zh) 2006-08-23
AU2004255456B2 (en) 2010-06-24
DE602004030343D1 (de) 2011-01-13
TW200503752A (en) 2005-02-01
JP2009513542A (ja) 2009-04-02
AU2004255456A1 (en) 2005-01-20
EP1648502B1 (de) 2010-12-01
CN1822856B (zh) 2010-04-28
JP2011088916A (ja) 2011-05-06

Similar Documents

Publication Publication Date Title
ATE489967T1 (de) Hcv-vakzin
MA24422A1 (fr) Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotrachaite infectieuse aviaire.
FI894580L (fi) Non-a, non-b -hepatitisvirusantigenpeptid.
DK0725824T3 (da) Immunodominante humane T-celleepitoper af hepatitis C virus
DK1294893T3 (da) Modifikation af hepatitis B-kerneantigen
EA200501689A1 (ru) Соединения в качестве ингибиторов вируса гепатита c
DK1169339T3 (da) Makrocykliske peptider, der inhiberer Hepatitis C-virus NS3-protease
ES2188583T3 (es) Polipeptidos para el virus de la hepatitis c (hcv).
MA24458A1 (fr) Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire.
IS7830A (is) Bóluefni gegn lifrarbólgu C veiru (HCV)
ATE451119T1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
HRP20041085B1 (hr) Inhibitori hepatitis c virusa
JP2005501532A5 (de)
WO2006033995A3 (en) Thiazolidin-4-ones having anti-hepatitis b activity
TR200300544T1 (tr) Erimiş siklik bileşimler ve tıbbi kullanımları
ID18351A (id) Vaksin hidup rekombinan avian, yang sebagai vektor menggunakan virus laringotracheitis menular avian
FI910127L (fi) Genom-cdna och antigenpolypeptid av non-a-, non-b-hepatitisvirus.
DE69232906T2 (de) Detektion des Hepatis-C Virus.
EA200300129A1 (ru) Очистка антигенов вируса гепатита b (hbv) для применения в вакцинах
ATE170220T1 (de) Zusammensetzung verwendbar als therapeutisches mittel gegen chronische virale leberkrankheiten
ATE555794T1 (de) Heilmittel gegen hepatitis
AU2001290178A1 (en) A hepatitis c virus non-structural ns3/4a fusion gene
ATE534666T1 (de) Antikörper gegen den hepatitis c-virus e1e2 komplex und pharmazeutische zusammensetzungen
CU23031A1 (es) Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
EP1607091A4 (de) Antihepatitis-c-virus-mittel und anti-hiv-mittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1648502

Country of ref document: EP